Werth, V., Pike, M., Merrill, J., Morand, E., van Vollenhoven, R., Hobar, C., Delev, N., Shah, V., Sharkey, B., Wegman, T., Catlett, I., Banerjee, S., & Singhal, S. (2023). Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. SKIN The Journal of Cutaneous Medicine, 7(2), s114. https://doi.org/10.25251/skin.7.supp.114